<h1>Swiss pharma commits CHF1.5 billion to India in five years under new four-nation trade pact, boosting research and access</h1> A Swiss pharmaceutical company has committed to invest 1.5 billion Swiss francs in India over five years under the terms of a recently entered trade pact between India and a four-nation European trade bloc, which itself pledged USD 100 billion in investment over 15 years. The investment is directed to core business activities including research and development and collaboration with national health schemes to increase patient access. The agreement's entry into force may trigger additional foreign direct investment from multiple bloc-based firms and create enforceable commercial obligations and market-access expectations under the FTA framework.